Ultra low molecular weight heparin

Editors-in-Chief: C. Michael Gibson, M.S., M.D. Associate Editor-In-Chief: Ujjwal Rastogi, MBBS [1]

Deep Vein Thrombosis Microchapters
Home
Patient Information
Overview
Classification
Pathophysiology
Causes
Differentiating Deep vein thrombosis from other Diseases
Epidemiology and Demographics
Risk Factors
Triggers
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Approach
Assessment of Clinical Probability and Risk Scores
Assessment of Probability of Subsequent VTE and Risk Scores
History and Symptoms
Physical Examination
Laboratory Findings
Ultrasound
Venography
CT
MRI
Other Imaging Findings
Treatment
Treatment Approach
Medical Therapy
IVC Filter
Invasive Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Special Scenario
Upper extremity DVT
Recurrence
Pregnancy
Trials
Landmark Trials
Case Studies
Case #1
Ultra low molecular weight heparin On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Ultra low molecular weight heparin
CDC on Ultra low molecular weight heparin
Ultra low molecular weight heparin in the news
Blogs on Ultra low molecular weight heparin
Directions to Hospitals Treating Deep vein thrombosis
Risk calculators and risk factors for Ultra low molecular weight heparin

Overview

AVE5026 is a hemisynthetic, ultra low molecular weight heparin. It is obtained by highly selective and controlled depolymerization of heparin. It has an average molecular weight of 2000 to 3000 Da, as compared to 4000 to 5000 Da of other LMW heparins.